Trump announces Regeneron deal to lower Medicaid drug prices

President Donald Trump announced a deal with Regeneron to lower the cost of its pharmaceutical products for Medicaid. The agreement includes a price reduction on all current and future drugs, with the cholesterol drug Praluent being sold for $225 on the White House's drug discount website, TrumpRx. This announcement was made as part of the administration's drug pricing initiative, aimed at providing economic relief ahead of the November midterm elections.

Trump stated, "It should be front page news," emphasizing the importance of these agreements for voters. He noted that Regeneron is the last of 17 major pharmaceutical companies to finalize a deal with his administration, which has been promoting efforts to align U.S. drug prices with those in other developed nations. In addition to price reductions, Regeneron has committed to investing $27 billion in research, development, and manufacturing in the U.S.

The announcement comes amidst rising concerns over healthcare costs impacting American households. While the Trump administration has touted these deals as transformative, the details remain largely undisclosed. Health Secretary Robert F. Kennedy Jr. indicated that his team would share non-proprietary details with Congress, which has been pressing for transparency. The agreements have faced challenges, including a recent setback involving weight-loss drugmakers.

Regeneron also revealed that its new gene therapy, Otarmeni, has received FDA approval and will be available at no charge to eligible individuals. This approval was expedited under a program that has faced scrutiny from congressional Democrats.

Power Read: This deal strengthens Trump's position ahead of the midterms, potentially swaying voters concerned about healthcare costs. Regeneron's commitment to U.S. investment may enhance its standing with the administration, while the lack of transparency regarding the agreements exposes the administration to scrutiny from Congress. The strategic play here is clear: Trump aims to leverage these pharmaceutical partnerships to bolster his electoral prospects while navigating the complexities of healthcare policy.

What to watch: The upcoming midterm elections will reveal whether these drug pricing initiatives resonate with voters.